Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 74 (2) , 137-145
- https://doi.org/10.4065/74.2.137
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cytostatic activity of phenylacetate and derivatives against tumor cellsBiochemical Pharmacology, 1995
- Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetateJournal of Neurosurgery, 1995
- Transcriptional upregulation of TGF-α by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cellsCytokine, 1995
- Cellular accumulation of antineoplaston AS21 in human hepatoma cellsCancer Letters, 1995
- A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetyl-Glutamine, by Reversed-Phase, High Performance Liquid ChromatographyJournal of Liquid Chromatography, 1994
- 'Antineoplastons'Published by American Medical Association (AMA) ,1992
- Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFNα activity in‐vitroBritish Journal of Haematology, 1991
- Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen ExcretionPediatric Research, 1991
- A Biochemical Explanation of Phenyl Acetate Neurotoxicity in Experimental PhenylketonuriaJournal of Neurochemistry, 1985
- On the Possible Mechanism of Phenylacetate Neurotoxicity: Inhibition of Choline Acetyltransferase by Phenylacetyl‐CoAJournal of Neurochemistry, 1984